Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017 Apr 17:3:3.
doi: 10.1186/s40733-017-0031-4. eCollection 2017.

Asthma in the elderly: a double-blind, placebo-controlled study of the effect of montelukast

Michele Columbo  1
Affiliations
Case Reports

Asthma in the elderly: a double-blind, placebo-controlled study of the effect of montelukast

Michele Columbo. Asthma Res Pract. .

Abstract

Background: Little is known about asthma in the elderly as most studies of this condition have not included this patient group. It is unclear whether leukotriene antagonists benefit older asthmatics. We studied the effect of adding montelukast to the asthma treatment of elderly subjects.

Methods: Twenty-five subjects 65 years old and older with asthma were evaluated at week 0, 1, 5, 9, 13, and 17. Each subject received montelukast 10 mg and placebo each for 8 weeks in a cross-over design.

Results: Montelukast for 4 or 8 weeks did not significantly affect ACT, daily symptom scores, number of puffs of albuterol, spirometric values, peripheral blood eosinophils, or serum IgE vs. baseline or placebo. Similar results were obtained when analyzing subgroups of patients with lower ACT, lower FEV1, and higher eosinophils.

Conclusions: In this study of elderly asthmatics, montelukast had no effect on asthma symptoms, number of puffs of albuterol, spirometric values, peripheral blood eosinophils or serum IgE. These results will require confirmation in larger patient cohorts and in patients with uncontrolled asthmatic symptoms.

Keywords: Asthma; Elderly; Montelukast.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Hanania NA, King MS, Braman SS, Saltoun C, Wise RA, Enright P, et al. Asthma in the elderly: current understanding and future research needs - a report of a National Institute on Aging (NIA) workshop. J Allergy Clin Immunol. 2011;128(Suppl):4–24. doi: 10.1016/j.jaci.2011.06.048. - DOI - PMC - PubMed
    1. Adelroth E, Morris MM, Hargreave FE, O’Byrne PM. Airway responsiveness to leukotriene C4 and D4 and to methacholine in patients with asthma and normal controls. N Engl J Med. 1986;315:480–4. doi: 10.1056/NEJM198608213150803. - DOI - PubMed
    1. Wenzel SE. Middleton’s allergy. Principles and practice. Seventh. Maryland Heights: Mosby Elsevier; 2009. Antileukotriene therapy in asthma; pp. 1619–32.
    1. Mulder A, Gauvreau GM, Watson RM, O’Byrne PM. Effect of inhaled leukotriene D4 on airway eosinophilia and airway hyperresponsiveness in asthmatic subjects. Am J Respir Crit Care Med. 1999;159:1562–7. doi: 10.1164/ajrccm.159.5.9810095. - DOI - PubMed
    1. Reiss TF, Chervinsky P, Dockhorn RJ, Shingo S, Seidenberg B, Edwards TB. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma. Arch Intern Med. 1998;158:1213–20. doi: 10.1001/archinte.158.11.1213. - DOI - PubMed

Publication types

LinkOut - more resources